Recent Finacing
Recent Raise
BioTheryX is a clinical-stage biopharmaceutical company developing PHM molecular glues, PHM-based PROTACs, and multi-kinase inhibitors to selectively degrade disease-causing proteins for oncology, with BTX-A51 in Phase 1.
